Search
forLearn
5 / 801 resultslearn Grape stem cells
learn Epidermal Growth Factor
learn retinoic acid
learn Follistatin
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
Research
5 / 1000+ results
research 4-O-Methylhonokiol Protects HaCaT Cells from TGF-β1-Induced Cell Cycle Arrest by Regulating Canonical and Non-Canonical Pathways of TGF-β Signaling
4-O-Methylhonokiol helps protect skin cells from growth-stopping effects of a protein by regulating growth-related pathways.
research Cedrol restricts the growth of colorectal cancer in vitro and in vivo by inducing cell cycle arrest and caspase-dependent apoptotic cell death
Cedrol may be an effective treatment for colorectal cancer.
research Docosahexaenoic acid-acylated astaxanthin esters alleviate cisplatin- induced acute kidney injury by modulating the ferroptosis-related GPX4/xCT signaling pathway and reducing oxidative stress
Krill oil may help reduce prostate enlargement and growth.
research 丹蒽醌對人類惡性黑色素瘤細胞株(A375.S2)誘發細胞週期停滯及細胞凋亡之影響
Danthron from Rhubarb causes melanoma cells to stop growing and die.
research Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231
Glibenclamide slows breast cancer cell growth by stopping cell division.
Community Join
5 / 1000+ resultscommunity GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community Where can I find the results of GT20029 phase 1 study in the US/China. The actual data
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Where are GT20029 phase II results?
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.